Introduction-Tetanus, diphtheria, and acellular pertussis (Tdap) vaccination has been recommended for adolescents in the U.S. since 2006. Information on Tdap vaccination by provider recommendation is limited. The purpose of this study is to assess recent Tdap vaccination by provider recommendation status among adolescents aged 13-17 years.
INTRODUCTION
Pertussis, a respiratory illness caused by the bacteria Bordetella pertussis, remains endemic in the U.S. despite longstanding routine childhood pertussis vaccination. Since the 1980s, the number of reported pertussis cases has steadily increased, especially among adolescents and adults, likely due, in part, to waning immunity from the childhood vaccination series. [1] [2] [3] [4] Overall, there were 32,971 reported cases of pertussis during 2014 compared with 25,824 cases reported during 2004. 2 The number of pertussis cases is likely under-reported because individuals with pertussis, particularly adolescents and adults, can have nonspecific symptoms, with pertussis often going undiagnosed. 1, 3, 4 To protect adolescents from pertussis infection, the Advisory Committee on Immunization Practices recommended the tetanus, diphtheria, and acellular pertussis vaccine (Tdap) in 2005 as a routine booster vaccination for all adolescents aged 11-18 years, with a preferred age of administration at 11-12 years. 3, 4 Overall, by 2013, Tdap vaccination coverage was 84.7% among adolescents aged 13-17 years. 5 Provider recommendations are strongly associated with vaccination. [6] [7] [8] [9] Overall Tdap vaccination has been assessed previously, but comprehensive assessment of the impact of provider recommendation on Tdap vaccination coverage and prevalence of provider recommendation among adolescents at the national and state levels have not been reported previously. 5 The purpose of this study is to use data from the 2013 National Immunization Survey-Teen (NIS-Teen) to assess (1) Tdap vaccination and prevalence of provider recommendation of the vaccine; (2) provider recommendation and other factors associated with Tdap vaccination; and (3) coverage disparities among adolescents with and without a provider recommendation at the national and state levels. Such information is useful to develop tailored strategies to improve provider recommendation and Tdap vaccination coverage among adolescents.
METHODS
The 2013 NIS-Teen data were analyzed in 2016. NIS-Teen is a national, random-digit-dial telephone survey conducted by the Centers for Disease Control and Prevention (CDC). The objective of the NIS-Teen is to provide timely, detailed information regarding vaccination coverage among adolescents aged 13-17 years. Data are collected in the NIS-Teen in two phases. In the first phase, a random-digit-dial telephone interview is conducted to identify households with age-eligible adolescents (aged 13-17 years at the time of interview) and to collect demographic information from the parent or guardian on adolescent, maternal, and household characteristics. Also, the interview includes questions on the adolescent's reported vaccination history. After completing the interview, consent is requested to contact the vaccination provider(s). If consent is obtained, the adolescent's vaccination providers are mailed a questionnaire to collect provider-reported vaccination histories for each recommended adolescent vaccine and selected childhood vaccines. 5, 10 In 2013, the NIS-Teen sampling plan included independent samples of households with a landline and also households with a cell phone. 5, 10 In total, there were 18,948 adolescents with adequate provider data from landline (representing 62.0% of all adolescents from the landline sample with completed household interviews) and cell samples (representing 56.4% of all adolescents from the cell phone sample with completed household interviews) combined excluding the U.S. Virgin Islands and Guam. The Council of American Survey Research Organizations response rates were 51.1% for landline and 23.3% for cell phone. 5, 10, 11 Provider recommendation status was assessed by asking parents/guardians whether they have received a provider recommendation of the vaccine. Tdap vaccination was assessed by provider recommendation and controlled covariates that may be associated with vaccination coverage empirically or based on previous studies, 6-8 which included age group; gender; race/ethnicity; mother's educational level; mother's marital status; mother's age; birth country; poverty level; type of health insurance and vaccine finance; number of physician contacts within the past 12 months; provider-reported healthcare visit at age 11-12 years; number of vaccination providers reported by parents; vaccination facility type (public, private, hospital, sexually transmitted disease/school/teen clinics, mixed [including facilities in more than one category such as private, public, hospital, sexually transmitted disease/ school/teen clinics], and others [such as military, Special Supplemental Nutrition Program for Women, Infants, and Children clinics, and pharmacies]); metropolitan statistical area; and U.S. Census region. Prevalence of provider recommendation and vaccination coverage at the state level were assessed. Vaccination by middle school entry requirement, which was in effect as of 2013 based on information from immunization.org, was also evaluated. 12 The authors used SUDAAN, version 11.0.1, to calculate point estimates and 95% CIs adjusted for the complex sample design of NIS-Teen. All analyses account for the complex sampling plan of NIS-Teen and the survey sampling weights. 5, 6 Chi-square tests were used to examine differences in population distribution between those with and without a provider recommendation. The study used t-tests to examine prevalence of provider recommendation and vaccination coverage compared with the reference group within each variable, as well as national and state-specific vaccination coverage differences between those with and without a provider recommendation. All tests were conducted with the significance level set at α < 0.05. Multivariable logistic regression and predictive marginal modeling were conducted to derive the adjusted prevalence ratio (PR). NIS-Teen was approved by CDC, National Center for Health Statistics Research Ethics Review Board, and the NORC at the University of Chicago IRB. Table 1 shows the demographic characteristics of the study population. Overall, a majority of adolescents were non-Hispanic white (55.0%); had mothers with more than a high school education (62.1%); had mothers who are currently married (66.1%); were born in the U.S. (95.5%); were living in a household with an income >133% of the federal poverty level (66.9%); had one vaccination provider (50.6%); had at least one physician contact within the past year (83.6%); and received all reported vaccination from providers in a private facility (50.4%).
RESULTS
Overall, only 56.9% of adolescents aged 13-17 years received a provider recommendation for Tdap (Table 1) . Number of physician contacts in the past year and well-child visit at age 11-12 years were significantly associated with prevalence of provider recommendation for Tdap vaccine; this is particularly important because physician contacts and well-child visits might provide chances for providers to recommend vaccines to their patients. Prevalence of provider recommendation was significantly higher among those with one (56.5%); two to three (60.4%); and four or more (58.8%) physician contacts compared with those without a physician contact within the past year (47.5%). Prevalence of provider recommendation was significantly higher among those who had a well-child visit at age 11-12 years (63.9%) compared with those who did not (48.4%). Other variables that were significantly associated with prevalence of provider recommendation included race/ethnicity, mother's educational level, mother's marital status, mother's age, adolescent's birth county, poverty level, medical insurance, number of vaccination providers, metropolitan statistical area, region, and vaccination facility type. Additionally, prevalence of provider recommendation was the lowest among adolescents with mothers having less than high school education (34.4%), then born outside the U.S. (36.6%), and highest among those with mother's education beyond college graduation (70.4%) ( Table 1) .
Overall, Tdap vaccination coverage was 84.7% among adolescents aged 13-17 years. Coverage was significantly higher among adolescents with a provider recommendation (88.6%) compared with those without a provider recommendation (80.5%) (p < 0.05) ( Table  2 ). Coverage was significantly higher among adolescents aged 13-15 years (86.3%) compared with those aged 16-17 years (82.3%) (p < 0.05) ( Table 2 ). In multivariable analyses, characteristics independently associated with a higher likelihood of Tdap vaccination included receiving a provider recommendation (PR=1.06); being of Hispanic ethnicity (PR=1.05); having two three physician contacts in the past 12 months (PR=1.05); having one or two vaccination providers (PR=1.07, and PR=1.06, respectively); and receiving vaccinations from more than one type of facility (PR=1.09) (p < 0.05) ( Table 3) . Adolescents aged 16-17 years (PR=0.97); those not having a well-child visit at age 11-12 years (PR=0.88); and those living in the South (PR=0.95) had a lower likelihood of Tdap vaccination (p < 0.05) ( Table 3) . Coverage among adolescents with a provider recommendation was significantly higher across the majority of demographic and access to care characteristics compared with those without a provider recommendation (Table 2) .
By state, prevalence of provider recommendation for Tdap among all adolescents aged 13-17 years ranged from 36.6% in Mississippi to 77.9% in Maine with a median of 57.6% (Table 4) . Tdap vaccination coverage among all adolescents aged 13-17 years ranged from 59.3% in Mississippi to 95.5% in Rhode Island with a median of 84.2%. Tdap coverage among those with a provider recommendation ranged from 72.1% in Mississippi to 97.5% in North Dakota with a median of 88.6% compared with those without a provider recommendation (ranging from 52.9% in Mississippi to 96.4% in Rhode Island with a median of 81.2%) ( Table 4 ). Point estimates of Tdap vaccination coverage were statistically significantly higher among adolescents with a provider recommendation compared with adolescents without a provider recommendation in 17 states (Table 4 ). Coverage differences ranged from -2.1% in Virginia to 26.2% in Maryland with a median of 7.2%. State prevalence of receiving provider recommendation also correlated positively with overall state Tdap vaccination coverage (r =0.50, p < 0.01). Among 11 states without a middle school vaccination requirement as of 2013, eight states had lower Tdap vaccination coverage than national coverage though only coverage in South Dakota was significantly lower than the national coverage (Table 4) .
DISCUSSION
The findings indicate that Tdap coverage was significantly higher among adolescents with a provider recommendation compared with those without a provider recommendation. Provider recommendation was associated with higher Tdap coverage across many demographic and access to care factors and 17 states. To the authors' knowledge, this is the first study to examine the association between provider recommendation and Tdap vaccination among adolescents. Although the impact of provider recommendation on Tdap vaccination was not reported previously, the impact of provider recommendation on other vaccinations was documented. One study showed that hepatitis A vaccination coverage was 86.9% among adolescents with a provider recommendation compared with those without a provider recommendation (65.5%). 6 Another study indicated that human papillomavirus vaccination coverage (one or more doses) was 58.3% among adolescents with a provider recommendation compared with those without a provider recommendation (20.7%). 13 Recommendations from providers increase parental acceptance of vaccination, and parents change their minds about delaying and refusing vaccines because of information or assurances from healthcare providers. 14, 15 Provider recommendations for vaccination are strongly associated with a patient's decision to get vaccinated. Studies have consistently shown that provider recommendation is the strongest predictor of vaccination. [6] [7] [8] [9] However, the present study showed that about 43% of parents of adolescents reported not receiving a provider recommendation for the vaccine. Providers should strongly recommend vaccines to parents and adolescents. Parents usually trust physicians' opinions more than anyone else's when it comes to vaccinations. 9 Providers should use every opportunity to vaccinate adolescent patients; review medical records to assess vaccination status when they see adolescents for sick visits and sports physicals; use patient reminder and recall systems (such as automated postcards, phone calls, and text messages); educate parents about the diseases that can be prevented by adolescent vaccines as parents may know very little about pertussis; and implement policies for standing orders so that patients can receive vaccines without a physician examination or individual physician order. 9, [16] [17] [18] Additionally, high coverage can be achieved even without provider recommendation: Overall, coverage is 80% among adolescents without a provider recommendation. Several reasons that may partially account for why coverage is relatively high among those without a provider recommendation included the following: the parent forgot about recommendation; vaccination was recommended and offered but the parent did not interpret the interaction as a recommendation; and the parent asked for the vaccine (e.g., to comply with state immunization pre-matriculation requirements) so a provider recommendation was not needed.
Tdap vaccination. People who have more physician contacts may have more opportunities to discuss their vaccination status and receive vaccination. But, for many adolescents, the provider visits in the last 12 months might not be the times they would have received Tdap vaccination (which probably occurred at age 11 or 12 years, whereas the sample was adolescents aged 13-17 years). The Advisory Committee on Immunization Practices and partner organizations, including the American Academy of Pediatrics, American Medical Association, and Society for Adolescent Medicine, recommend a well-child visit for children aged 11-12 years to receive recommended vaccinations and indicated preventive services such as vaccinations required to attend middle school. 7, 19, 20 Even though the wellchild visit for children aged 11-12 years provides a good opportunity to discuss vaccination status and receive vaccinations, based on this study, only 40.2% of adolescents had a wellchild visit at age 11-12 years. Efforts are needed to increase preventive healthcare utilization, especially at age 11-12 years, so that preteens can receive recommended vaccinations and other preventive services. In addition, providers should be encouraged to review and, if necessary, administer recommended adolescent vaccinations at all healthcare visits, in addition to the preteen visit at age 11-12 years, to prevent missed opportunities for vaccination.
Overall, Tdap vaccination coverage among adolescents aged [13] [14] [15] [16] [17] [21] [22] [23] [24] and prevalence of provider recommendation for this vaccine was 36.1% in 2013 (CDC unpublished data). As the vaccination program becomes more mature, coverage could be increased further. [21] [22] [23] [24] The providers' role is important for improving vaccination coverage after Advisory Committee on Immunization Practices recommendations for adolescents are made. Providers should strongly recommend adolescent vaccines to their parents and use every opportunity to assess vaccination status and vaccinate adolescent patients.
Substantial differences in coverage among states and regions were observed for Tdap vaccination among adolescents. Variation in state coverage could be due to differing medical care delivery infrastructure, socioeconomic factors, state laws, effectiveness of state and local immunization programs, population attitudes toward vaccinations, immunization resources, reimbursement for vaccines, vaccine administration, variations in prevalence of receipt of provider recommendation for Tdap, and other factors. 12,25-35 Assessing local, state, and national vaccination programs is necessary for evaluating progress. For example, state-level comparisons may aid in designing tailored intervention programs and sharing best practices. Some states achieved very high coverage, and states with low prevalence of provider recommendation and lower Tdap coverage may particularly benefit from provider-based interventions such as provider assessment and feedback, provider reminders, and a standing orders program.
Forty states have middle school requirements for Tdap vaccination as of 2013. 12 Pertussis outbreaks may occur in middle and high schools and can be highly disruptive and costly to schools and health departments. 36 The findings from this study showed that among 11 states without a middle school vaccination requirement, eight states had lower Tdap vaccination coverage than national coverage though only coverage in South Dakota was significantly lower than national coverage. Previous studies also indicated that middle school entry requirements have helped increase coverage for some vaccinations. 37-39
Limitations
The findings of this study are subject to several limitations. First, household response rates were 51.1% (landline households) and 23.3% (cell phone households), respectively. Only 59.5% (landline) and 54.5% (cell phone) of completed household interviews also had adequate provider-reported vaccination data. Some bias may remain after weighting adjustments designed to mitigate potential bias from incomplete data from the sample frame and non-response. [40] [41] [42] [43] Second, some provider-reported vaccination histories might not include all received vaccinations (e.g., vaccinations administered in nontraditional settings such as emergency departments) and might have underestimated vaccination coverage. Finally, reporting of provider recommendation by parents is subject to recall bias if parents did not accurately remember whether or not a recommendation had occurred, particularly parents of older adolescents who had been vaccinated years earlier.
CONCLUSIONS
The current study indicated that Tdap coverage was significantly higher among adolescents with a provider recommendation (88.6%) compared with those without a provider recommendation (80.5%). However, 43% of parents of adolescents did not receive a provider recommendation. Higher coverage can be achieved given that very high coverage was observed in some states and subgroups. For example, Tdap vaccination coverage was >90% among six states and >93% among those with a well-child visit. To further improve Tdap vaccination coverage, vaccine education efforts should target healthcare providers to increase rates of provider recommendation for Tdap. Additionally, evidence-based strategies such as standing orders and provider reminders alone or health systems interventions in combination should be taken to further improve Tdap vaccination coverage. Providers and parents should use every healthcare visit, whether for health problems, well-checks, or physicals for sports, school, or camp, as an opportunity to review adolescents' vaccination histories and ensure that every adolescent receives Tdap and other recommended vaccines. 44, 45 Additionally, to increase Tdap coverage, intervention programs should be particularly targeted to the demographic and access to care groups where vaccination coverage was low based on this study. Provider-based interventions such as provider assessment and feedback, provider reminders, and standing orders programs should be enhanced for states with low prevalence of provider recommendation and lower Tdap coverage. State programs are encouraged by CDC to promote adolescent vaccinations within their communities by increasing awareness about the importance and benefits of adolescent vaccination. Federal, state, and local governments and community partners should collaborate to further improve vaccination coverage among adolescents. 
